CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

The scores also enable researchers to assess the spatial relationships critical to the mechanisms of antibody–drug conjugates (ADCs), such as the bystander effect, where a drug impacts not only the ...

Roche and Oxford BioTherapeutics announced a multi-year collaboration on the research and development of novel antibody–drug conjugates (ADC). Roche will pay the UK-based company $36 million upfront ...

Part 1 covered the fundamental frequency-response measurement method and how to use it to measure the analog input bandwidth for an ADC. Part 2 discusses the DAC’s analog output and offers tips to ...

Japan-based Taiho Pharmaceuticals on Monday said it will acquire Switzerland’s Araris Biotech and its antibody-drug conjugate technology ... which it claims can provide more stable and more potent ...

Attribution (BY): Credit must be given to the creator. Research into antibody-drug conjugates (ADCs) is currently at an inflection point due to recent clinical impact. ADC biotransformation analysis ...

As have their armored counterparts, the antibody-drug conjugates (ADCs) ado-trastuzumab emtansine (T-DM1; Kadcyla) and trastuzumab deruxtecan. In the phase 2 PATRICIA trial (NCT02536339), 5 the ...

Zymeworks has pumped the brakes on plans to take one of its antibody-drug conjugates into ... “remains a highly differentiated, IND-ready ADC with encouraging preclinical data and strong ...